Case Study: Evaluation of Anticancer Treatment and Cardiovascular Safety in a Breast Cancer Patient with Pre-existing Cardiovascular Conditions - Top-Institutions - MDSpire

Case Study: Evaluation of Anticancer Treatment and Cardiovascular Safety in a Breast Cancer Patient with Pre-existing Cardiovascular Conditions

  • By

  • Minghui Long

  • Boni Ding

  • April 28, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Cardio-Oncology
    • Breast Cancer
    • Cardiology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Cardio-Oncology
    • Breast Cancer
    • Cardiology
    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Cardio-Oncology
    • Breast Cancer
    • Cardiology
    • Oncology

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Cardio-Oncology
    • Oncology

  • #5

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Cardio-Oncology
    • Breast Cancer
    • Cardiology
    • Oncology

Original Source(s)

Case Study: Evaluation of Anticancer Treatment and Cardiovascular Safety in a Breast Cancer Patient with Pre-existing Cardiovascular Conditions

  • by Minghui Long, Boni Ding

  • April 28, 2026

Related Content

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

  • by

  • May 26, 2026

  • 5 min
When should you get a mammogram? Conflicting advice makes it hard to know

Multi-parametric MRI habitat radiomics with interpretable machine learning for early prediction of axillary lymph node metastasis in triple-negative breast cancer